NervGen Pharma Corp logo

NervGen Pharma Corp

OTCPK:NGENF (Canada)   Ordinary Shares
$ 1.53 +0.034 (+2.27%) 10:09 PM EST
At Loss
Market Cap:
$ 105.82M
Enterprise V:
$ 97.44M
Volume:
33.55K
Avg Vol (2M):
72.13K
Also Trade In:
Volume:
33.55K
At Loss
Avg Vol (2M):
72.13K

Business Description

Description
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Name Current Vs Industry Vs History
Cash-To-Debt 58.89
Equity-to-Asset -0.15
Debt-to-Equity -0.1
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -2.6
3-Year EPS without NRI Growth Rate 5.8
3-Year FCF Growth Rate 0.5
Name Current Vs Industry Vs History
5-Day RSI 48.77
9-Day RSI 47.92
14-Day RSI 45.95
6-1 Month Momentum % 18.38
12-1 Month Momentum % 35.29

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.83
Quick Ratio 0.83
Cash Ratio 0.77

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.2
Shareholder Yield % 0.05
Name Current Vs Industry Vs History
ROE % -329.18
ROA % -124.37
ROIC % -201.06
ROC (Joel Greenblatt) % -9075.36
ROCE % -322.23

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -5.95
EV-to-EBITDA -5.99
EV-to-FCF -11.8
Earnings Yield (Greenblatt) % -16.81
FCF Yield % -7.8

Financials

NGENF's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:NGENF

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

NervGen Pharma Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.282
Beta 0.98
Volatility % 75.67
14-Day RSI 45.95
14-Day ATR ($) 0.097278
20-Day SMA ($) 1.5273
12-1 Month Momentum % 35.29
52-Week Range ($) 1.15 - 2.99
Shares Outstanding (Mil) 69.93

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NervGen Pharma Corp Filings

Filing Date Document Date Form
No Filing Data

NervGen Pharma Corp Stock Events

Financials Calendars
Event Date Price($)
No Event Data

NervGen Pharma Corp Frequently Asked Questions

What is NervGen Pharma Corp(NGENF)'s stock price today?
The current price of NGENF is $1.53. The 52 week high of NGENF is $2.99 and 52 week low is $1.15.
When is next earnings date of NervGen Pharma Corp(NGENF)?
The next earnings date of NervGen Pharma Corp(NGENF) is .
Does NervGen Pharma Corp(NGENF) pay dividends? If so, how much?
NervGen Pharma Corp(NGENF) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1